II-III期卵巢癌辅助化疗未推荐中的种族差异
这项回顾性队列研究利用2004至2015年美国国家癌症数据库(NCDB)数据,分析II-III期卵巢癌初次手术后未获辅助化疗推荐的患者因素。48,245例中522例(1.08%)因禁忌未接受辅助化疗。多因素分析显示年龄≥70岁、Charlson-Deyo合并症评分非零和黑人种族是独立预测因素;黑人患者未获推荐的中位年龄更轻且5年生存率更低。
要点
- 在48,245例II-III期卵巢癌手术患者中,522例(1.08%)因判定为禁忌而未接受辅助化疗。
- 未获辅助化疗推荐的独立预测因素包括年龄≥70岁、Charlson-Deyo合并症评分非零和黑人种族。
- 黑人患者未获推荐的中位年龄为64.5岁 vs 72岁,5年生存率为25.9% vs 40.3%(p<0.0001)。
核心结论
- 因患者危险因素(合并症、高龄)被判定为禁忌而未接受辅助化疗的卵巢癌手术患者年龄更大且合并症评分更高。
- 即使控制这些差异后,黑人患者仍被不成比例地不推荐化疗,且与更差生存相关。
- 确定辅助化疗资格需要个体化方法,种族偏见对风险估计的可能影响应进一步研究。
研究设计与样本
- 回顾性队列研究,使用2004至2015年美国国家癌症数据库(NCDB)数据。
- 纳入II-III期卵巢癌接受初次手术的患者,共48,245例符合入选标准。
- 采用多因素logistic回归分析与未推荐辅助化疗相关的因素,Kaplan-Meier分析评估生存数据。
主要发现
- 48,245例中522例(1.08%)因判定为禁忌而未接受辅助化疗。
- 未获辅助化疗推荐的独立预测因素:年龄≥70岁(aOR=2.43,p<0.0001)。
- 未获辅助化疗推荐的独立预测因素:Charlson-Deyo合并症评分1分(aOR=1.41,p=0.002)、评分≥2分(aOR=2.57,p<0.0001)。
- 未获辅助化疗推荐的独立预测因素:黑人种族(aOR=2.12,p<0.0001)。
- 黑人患者未获辅助化疗推荐的中位年龄为64.5岁 vs 72岁,5年生存率为25.9% vs 40.3%(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为确定辅助化疗资格需要个体化方法,种族偏见对风险估计的可能影响应进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify patient factors associated with not receiving a recommendation for adjuvant chemotherapy after primary surgery for ovarian cancer. METHODS: This retrospective cohort study used the National Cancer Database (NCDB) data from 2004 to 2015 to identify patients with stage II-III ovarian cancer who underwent primary surgery. Multivariate logistic regression analyses evaluated factors associated with notation in the NCDB that "chemotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age)." Survival data were assessed via Kaplan-Meier analyses. RESULTS: Of the 48,245 patients who met the inclusion criteria, 522 (1.08%) did not receive adjuvant chemotherapy because it was determined to be contraindicated. In multivariate analyses, independent predictors for not receiving a recommendation for adjuvant chemotherapy were age ≥ 70 years old (adjusted odds ratio, aOR = 2.43, p < 0.0001), non-zero Charlson-Deyo comorbidity scores (score 1, aOR = 1.41, p = 0.002; score ≥ 2, aOR = 2.57, p < 0.0001), and Black race (aOR = 2.12, p < 0.0001). For Black patients, recommendation against adjuvant chemotherapy occurred at a younger median age (64.5 years vs. 72 years) and was associated with lower 5-year survival (25.9% vs. 40.3%, p < 0.0001). CONCLUSIONS: Patients with ovarian cancer who underwent surgery but did not receive chemotherapy "because it was contraindicated due to patient risk factors" were older and had higher comorbidity scores. Even after controlling for these differences, Black patients were disproportionately not recommended for chemotherapy, which was associated with worse survival. Determining eligibility for adjuvant chemotherapy requires an individualized approach, and the possible influence of racial bias on risk estimation should be further investigated.
引用
- Matthews BJ, Qureshi MM, Fiascone SJ, et al. Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer. Gynecol Oncol. 2021. PMID: 34785030. doi:10.1016/j.ygyno.2021.10.090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。